For the industrial layout, this pharmaceutical company invested 500 million yuan to set up a subsidiary!

【Pharmaceutical Network Enterprise News】On September 21, Northeast Pharmaceutical issued an announcement that it intends to invest 500 million yuan in its own funds to establish a wholly-owned subsidiary "Northeast Pharmaceutical Group (Shanghai) Biotechnology Co.
, Ltd.
" (tentative), and the company holds 100% of its equity
.

Northeast Pharmaceutical said that the establishment of a wholly-owned subsidiary with its own funds can accelerate the implementation of ADC drugs and CAR-T cell therapy technical cooperation projects introduced by agreement with MedAbome, Inc.
in the
United States.

The subsidiary initially focused on promoting the research and development of cooperative projects to meet the clinical product preparation and build a small production platform
for culture media.

In fact, a common reason for pharmaceutical companies to set up subsidiaries is "industrial layout"
.

Since the beginning of this year, in addition to Northeast Pharmaceutical, in fact, many companies have also acquired and set up wholly-owned subsidiaries
for these reasons.

For example, Sunflower Pharmaceutical announced at the end of July that the company intends to invest 54 million yuan to establish a wholly-owned subsidiary, Beijing Sunflower Pharmaceutical Research Co.
, Ltd.
, to build a research and development platform focusing on children's preparation technology, so as to further strengthen the company's main business of children's medicine, and strengthen the research and development of children's drugs, and actively respond to policy guidance
.

The company said that it will make full use of the location advantage of the company to be established, absorb and introduce talents in the field of children's preparations at home and abroad, and is committed to the introduction of children's preparation technology at home and abroad, the research and development of children's imitation preparations, and the upgrading
of existing varieties and technologies in the field of children's drugs in the company.

On May 12, Saisheng Pharmaceutical issued an announcement that according to the company's strategic planning and business development needs, it held the 17th meeting of the fourth board of directors on May 12, 2022, deliberated and passed the "Proposal on the Establishment of a Wholly-Owned Subsidiary for Overseas Investment", and agreed that the company would invest 100 million yuan to establish a wholly-owned subsidiary "Jilin Anniu Animal Husbandry Biotechnology Co.
, Ltd.
" (provisional name, and finally subject to industrial and commercial registration
。
This investment will promote the company's expansion of the development of biological breeding business areas such as breeding cattle breeding, in vitro embryo technology application, gene editing, etc.
, and further promote the company's strategic layout
in the field of life sciences and health.

In addition to the "industrial layout", of course, there are also some pharmaceutical companies that set up subsidiaries for enterprise transformation, such as Shandong Buchang Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Buchang Pharmaceutical") is a typical
example.

In addition to the transformation into a scientific research enterprise, Buchang Pharmaceutical also intends to further lay out the big health and increase the size of biomedicine
.

In 2019, Zhejiang Buchang Health Technology Co.
, Ltd.
, a holding subsidiary, plans to set up two subsidiaries out of the needs of business development; Capital increase in Sichuan Luzhou Buchang Biopharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of Shandong Buchang Pharmaceutical
.

In fact, in recent years, through the establishment of companies with the intention of laying out products, improving product structure, and carrying out the layout of great health or increasing biomedicine, there are many
enterprises.

However, it should be noted that at the same time, there are not a few
who split and cancel subsidiaries.

In this regard, industry analysts believe that behind the various actions of these pharmaceutical companies, they are all aimed at making corporate strategies more focused and better developing
.

In the future, in the context of the rapid iteration of the pharmaceutical industry, these behaviors will become the norm
.

But no matter how it develops, in order to have long-term competitiveness, for enterprises, only internal and external repairs can be achieved
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.